Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial, page-285

Hi @Wilba32 ! Thought I'd jump on this sleuthing run..

Looking through the clinicaltrials.gov site searching 'COVID-19' and 'NIH', it spat out 71 replies.

Parsing through the search, I was looking for any NIH involvement, whether as a sponsor or study-support, and it yielded some interesting results.

1. The HCQ study in the Philippines was withdrawn (effective 9 Nov)

2. There's a B and T-cell repertoire and immune response study (not a treatment, just an investigation)

3. There's a P2 RCT trial looking at Fostamatinib (an SYK inhibitor - basically it inhibits pro-inflammatory cytokines by monocytes and macrophages (similar to Rem-L's MOA in one facet, but I fail to see how its gonna address the need for anti-inflammatory cytokines that plays a role in stimulating regeneration in inflamed tissue - this is the big reason why we were seeing more light being shed on the 'long covid' patients, and why Rem-L, in our generation, needs to be approved precisely for the complete eradication of C-19 in even the recovered patients.), decreased production of neutrophil extracellular traps (NETs) by neutrophils, and inhibition of platelet aggregation; three pathways that are mediated through Fc receptors (FcR) recognition of antigen-antibody complexes or activation of c-type lectin receptors (CLEC)

So to answer you, Rem-L's the only NIH one that's the most promising right now.